Victor Pina, MD
Gastroenterology · Miami, FLNPI 1164403846
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 433 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations.
Across 433 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- AbbVie$1K
- Intercept Pharmaceuticals, Inc.$848
- Johnson & Johnson$549
- Ipsen Biopharmaceuticals, Inc$529
- Ardelyx, Inc.$407
- plus $2K from 26 others
Across 1 payment — averaging $23,490 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$23K
What the payments were for
- Food & beverage$7,21898%
- Education$1492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 106 | $1,456 |
| AbbVie(2 entities) | 69 | $1,313 |
| Intercept Pharmaceuticals, Inc. | 48 | $848 |
| Johnson & Johnson | 33 | $549 |
| Ipsen Biopharmaceuticals, Inc | 25 | $529 |
| Ardelyx, Inc. | 24 | $407 |
| Redhill Biopharma Inc. | 33 | $367 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $276 |
| Phathom Pharmaceuticals, Inc. | 11 | $238 |
| Gilead | 5 | $170 |
| Nestle Healthcare Nutrition Inc. | 14 | $166 |
| Napo Pharmaceuticals Inc | 1 | $125 |
| Braintree Laboratories, Inc. | 6 | $107 |
| Vivus LLC | 6 | $105 |
| Lilly USA, LLC | 5 | $103 |
| Evoke Pharma, Inc. | 6 | $94 |
| Ironwood Pharmaceuticals, Inc | 5 | $81 |
| Madrigal Pharmaceuticals | 4 | $79 |
| Bristol Myers Squibb | 3 | $49 |
| Daiichi Sankyo Inc. | 2 | $37 |
| AstraZeneca | 2 | $36 |
| Pfizer | 2 | $34 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Alfasigma USA, Inc. | 2 | $28 |
| Covidien LP | 1 | $24 |
| Novo Nordisk | 1 | $22 |
| Dova Pharmaceuticals | 1 | $18 |
| QOL Medical, LLC | 2 | $17 |
| Romark Laboratories, LC | 1 | $17 |
| Medtronic | 1 | $17 |
| Merck | 1 | $16 |
| Organon | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,367 in reported general payments places this provider in the 70th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SutabSod Sulf/Pot Chloride/Mag Sulf | 36 | $5,919 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 26 | $4,407 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 16 | $2,010 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 22 | $1,315 |
| CholestyramineCholestyramine (With Sugar) | 11 | $952 |
| Famotidine | 37 | $628 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 42 | $624 |
| Omeprazole | 33 | $441 |
| Dicyclomine Hcl | 16 | $409 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 15 | $243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Braintree Laboratories, Inc.Sutab, Suflave | $107 | $7,93052 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Miami
- Lukasz KwapiszMiami$1.2M
- Joanna LopezMiami$670K
- Jerry MartelMiami$511K
- Andres GelrudMiami$208K
- Maria HernandezMiami$197K
- George SanchezMiami$117K
- Jodie BarkinMiami$101K
- Javier ParraMiami$68K
- Samuel GidayOrlando$2M
- Jennifer Seminerio-DiehlOrlando$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.